Caribou Biosciences (CRBU)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	29.46 mm	29.46 mm	29.46 mm	29.46 mm	29.46 mm	29.46 mm
Cash burn (monthly)	(no burn)	1.67 mm	14.30 mm	13.63 mm	12.24 mm	11.48 mm
Cash used (since last report)	n/a	4.31 mm	37.03 mm	35.28 mm	31.69 mm	29.71 mm
Cash remaining	n/a	25.15 mm	-7.57 mm	-5.82 mm	-2.23 mm	-251.32 k
Runway (months of cash)	n/a	15.1	-0.5	-0.4	-0.2	-0.0

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CRBU institutional ownership history Ownership history

68.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	135	131	+3.1%
Opened positions	25	18	+38.9%
Closed positions	21	30	-30.0%
Increased positions	47	43	+9.3%
Reduced positions	27	32	-15.6%

13F shares	Current	Prev Q	Change
Total value	91.47 bn	101.76 bn	-10.1%
Total shares	64.04 mm	62.99 mm	+1.7%
Total puts	110.90 k	70.70 k	+56.9%
Total calls	151.50 k	147.70 k	+2.6%
Total put/call ratio	0.7	0.5	+52.9%

Largest owners	Shares	Value	Change
BlackRock	6.56 mm	$10.44 bn	-9.3%
PFE Pfizer	4.69 mm	$7.46 bn	0.0%
Vanguard	4.57 mm	$7.26 bn	-1.1%
Partner Fund Management	3.88 mm	$6.16 bn	-10.0%
Rachel E. Haurwitz	3.35 mm	$20.50 mm	0.0%
MS Morgan Stanley	2.75 mm	$4.37 bn	+129.5%
Farallon Capital Partners	2.58 mm	$41.11 mm	0.0%
JPM JPMorgan Chase & Co.	2.50 mm	$3.97 bn	+475.9%
Kynam Capital Management	2.41 mm	$3.83 bn	+2.1%
Schonfeld Strategic Advisors	2.11 mm	$3.36 bn	+28.4%

Largest transactions	Shares	Bought/sold	Change
BAC Bank of America	1.77 mm	-2.80 mm	-61.3%
JPM JPMorgan Chase & Co.	2.50 mm	+2.06 mm	+475.9%
MS Morgan Stanley	2.75 mm	+1.55 mm	+129.5%
Jacobs Levy Equity Management	1.21 mm	+1.21 mm	NEW
Point72 Asset Management	1.02 mm	-1.11 mm	-51.9%
BlackRock	6.56 mm	-669.18 k	-9.3%
Renaissance Technologies	0.00	-594.20 k	EXIT
Schonfeld Strategic Advisors	2.11 mm	+467.74 k	+28.4%
Partner Fund Management	3.88 mm	-430.21 k	-10.0%
Two Sigma Advisers	1.47 mm	+416.60 k	+39.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CRBU insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
14 Mar 25	Rachel E. Haurwitz	Common Stock	Buy	Acquire P	Yes	No	1.02	20,000	20.40 k	3,369,395
20 Feb 25	Braunstein Scott	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	1.41	40,500	57.11 k	40,500
20 Feb 25	Guggenhime Andrew	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	1.41	40,500	57.11 k	40,500
20 Feb 25	Johnson David Lee	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	1.41	40,500	57.11 k	40,500
20 Feb 25	Natalie Sacks	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	1.41	40,500	57.11 k	40,500

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Caribou Biosciences Q1 EPS $(0.43) Beats $(0.44) Estimate, Sales $2.35M Beat $1.75M Estimate

8 May 25

Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.44) by 2.27 percent. This is a 6.52 percent increase over losses of $(0.46) per share from

HC Wainwright & Co. Maintains Buy on Caribou Biosciences, Lowers Price Target to $3

28 Apr 25

HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $9 to $3.

Caribou Biosciences Prioritizes Oncology Pipeline, Streamlines Operations to Focus on CB-010 and CB-011 Clinical Programs, With Clinical Data Disclosures Now Planned For H2 2025

24 Apr 25

-- Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 ---- Two robust clinical datasets from CB-010 and CB-011 now expected to be

Press releases

From Benzinga Pro

Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference

6 May 25

BERKELEY, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou's